Cannabis investors woke up to a negative sell-side take on Tilray Inc. TLRY Friday, with Jefferies calling the Canadian company's valuation unjustified.
Trending Investment Opportunities
The Analyst
Jefferies analyst Owen Bennett initiated coverage of Tilray with an Underperform and $61 price target.
The Thesis
Too much value is assigned to Tilray's partnerships with Anheuser Busch Inbev NV BUD and Authentic Brands Group, Bennett said in the initiation note.
"We appreciate [Tilray] is well-placed in medical, but future value here will be driven by intellectual property, for which little visibility [exists] near-term," the analyst said.
The company's share structure also raise concerns of a risk of increased volatility, Bennett said.
Tilray’s valuation is too costly, the analyst said. "Our 10-year DCF-driven valuation suggests the stock is too expensive for its outlook, with an appropriate discount for long-term medical uncertainty not captured."
The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Alan Brochstein and many others.
Research suggests that Tilray lacks in the recreational market, as its focus has been on medical market, Bennett said.
Along with Canopy Growth Corp. CGC, Tilray is seen as a medical leader globally. Yet its lack of IP and drug formulations give Jefferies cause for concern about the company's long-term value, the analyst said.
Jefferies sees Tilray falling short of competitors Canopy and Aurora Cannabis Inc. ACB.
The research firm forecast 2020 calendar year sales for Canopy and Aurora that are 2.7x and 2.2x higher than Tilray's.
Price Action
Tilray shares were down 1.92 percent at $68.38 at the time of publication Friday.
Related Links:
Tilray Acquisition Of Manitoba Harvest Sets Early Pace For 2019 As 'Year Of Consolidation'
Tilray Harvests Medical Cannabis In Portugal, Ramps European Business
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!